Future studies aimed at further probing this mechanism are warranted, including use of overexpression and knockout studies to examine the ability for DCN expression levels to modulate ADC, inhibit tumor angiogenesis and/or proliferation, and synergize with concurrent anti-VEGF therapy to increase treatment efficacy. This evidence concerns the gene VEGFA and neoplasm.